The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study
NCT ID: NCT05402124
Last Updated: 2022-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2022-07-31
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Evaluate the feasibility of a real-world chemoprevention agent (CPA) intervention (3-months of daily low-dose acetylsalicylic (ASA)) in participants at increased risk for CRC (one or more high-risk adenomas removed during colonoscopy) based on participant uptake, adherence (days taking CPA), and adverse events;
2. Evaluate factors related to uptake and adherence of ASA using validated surveys and interviews.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
NCT00468910
Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer
NCT00331786
Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action
NCT02125409
Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer
NCT03957902
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers
NCT00410579
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a single arm (non-randomized), open-label prospective cohort pilot study.
Screening Phase: up to 2 weeks Treatment Phase: 90 days Follow-up Phase: 90 days
Screening Phase: up to 14 days. Participants will consent to being enrolled in the study and to the use of ASA for a 90 day period. Regardless of agreement to use ASA for the entire study period, all participants will complete 6 baseline questionnaires.
Active Treatment Phase: up to 90 days. Participants that agree to the use of ASAs will be instructed to take daily ASAs for 90 days. Participants will be contacted by telephone at 1, 2, and 3 months to determine adverse events, adherence, and discontinuation. At 3 months participants will fill out a chemoprevention questionnaire and the Adherence Barriers Questionnaire (ABQ).
Follow-up Phase: 90 days. During the follow-up phase, participants will not be provided with ASA through the study nor will a specific recommendation be made to continue ASA. All participants will be contacted via telephone at the end of this period to determine the prevalence of continued use of ASA on their own.
Total study commitment will be up to 194 days. After consent, participants complete a 90 day active treatment phase followed by a 90 day follow-up phase. The trial is expected to be completed within one year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASA 81mg
Acetylsalicylic acid delayed release tablets (81mg), single tablet taken once per day for 90 days.
acetylsalicylic acid delayed release tablets, 81mg
acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
acetylsalicylic acid delayed release tablets, 81mg
acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented history of high-risk adenomatous polyps diagnosed within the previous 12 months:
1. At least one villous or tubulovillous polyp of any size
2. At least one polyp with high-grade dysplasia of any size
3. At least one adenomatous polyp ≥1 cm in size
4. Three or more tubular adenomas \<1 cm in size
3. Not currently using ASA for another condition
Exclusion Criteria
2. Known allergy or hypersensitivity to ASA, salicylates or non-steroidal anti- inflammatory drugs.
3. Daily alcohol use \> 3 units
4. Regular use of aspirin or non-steroidal anti-inflammatory drugs (\> 2 dose/week)
5. Current use of corticosteroid (any dose) orally
6. Current use of methotrexate, valproic acid or digoxin
7. Currently taking any anti-cancer drug
8. Current use of anti-platelet agents or anticoagulants
9. Anticipated surgical procedure in the next 3 months
10. Current or past history of gastrointestinal ulcers
11. History of gastrointestinal bleeding (except hemorrhoidal or minor outlet type bleeding)
12. Known cirrhosis or hepatic impairment (for example, total bilirubin \>1.25 Upper Limit of Normal, International Normalized Ratio \>1.25)
13. Known bleeding disorder (hemorrhagic diathesis)
14. History of asthma or nasal polyps
15. History of colorectal cancer
16. Platelet count \< 120 or \> 450 (within previous 3 months)
17. Renal insufficiency (eGFR \< 90 within previous 3 months)
18. History of congestive heart failure or left ventricular ejection fraction \< 50 percent
50 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Canadian Cancer Society (CCS)
OTHER
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Hilsden
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Forzani & Macphail Colon Cancer Screening Centre, University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRC-CHAMP01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.